(Q72101958)

English

Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group

scientific article published on 01 January 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

based on heuristic

inferred from title

author name string

J P Gérard

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

M Héry

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

D Gedouin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

A Monnier

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

M J Goudier

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

J P Jacquin

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

F Plat

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

E Cabarrot

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

D Serin

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

M Namer

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

publication date

1 January 1993

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

45 Suppl 2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

60-67

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7693424%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

https://scigraph.springernature.com/pub.10.2165/00003495-199300452-00010

0 references

352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: Five-year results

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant tamoxifen and chemotherapy in stage II breast cancer: interim findings from NSABP protocol B-09

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy in stage II breast cancer: a brief overview of the NSABP clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7693424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q72101958&oldid=2004405925"